20
ALL10
Astellas Pharma1
Erasca3
Kronos Bio3
Kura Oncology3
Oryzon GenomicsYear
20
ALL2
20244
20235
20224
20215
2020DEALS // DEV.
20
ALL3
Deals17
DevelopmentsCountry
20
ALL10
JAPAN3
SPAIN7
U.S.A20
ALL1
AstraZeneca1
Blood and Marrow Transplant Clinical Trials Network2
BofA Securities1
European Commission2
Kotobuki Pharmaceutical13
Not ApplicableTherapeutic Area
20
ALL20
OncologyStudy Phase
20
ALL9
Approved1
Phase III5
Phase II4
Phase I/ Phase II1
IND EnablingDeal Type
3
ALL1
Funding2
Public OfferingProduct Type
20
ALL20
Small moleculeDosage Form
17
ALL3
Capsule2
Solution9
Tablet3
Tablet, Film CoatedLead Product
20
ALL1
ERAS-00710
Gilteritinib Fumarate3
Iadademstat3
Lanraplenib3
ZiftomenibTarget
10
ALL6
FLT31
LSD13
SykLead Product(s) : Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Not Applicable
Deal Type : Not Applicable
Kura Doses First Patient in KOMET-008 Trial of Ziftomenib with Standards of Care in AML
Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 1 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Product Name : KO-539
Product Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gilteritinib Fumarate,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clinical Trial Evaluates Triple-Drug Regimen for FLT3-Mutated AML
Details : Xospata (gilteritinib) is a receptor tyrosine kinase inhibitor being evaluated in combination with venetoclax and azacitidine for relapsed/refractory AML with an FLT3 mutation.
Product Name : Xospata
Product Type : Small molecule
Upfront Cash : Not Applicable
January 30, 2024
Lead Product(s) : Gilteritinib Fumarate,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
Details : The net proceeds will be used for the development of KO-539 (ziftomenib), a potent and selective inhibitor, being developed in combination with Xospata (gilteritinib), an inhibitor of FLT3, for the treatment of NPM1-mutated acute myeloid leukemia.
Product Name : KO-539
Product Type : Small molecule
Upfront Cash : Undisclosed
June 14, 2023
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-funded Warrants
Details : The net proceeds will be used for the development of KO-539 (ziftomenib), a potent and selective inhibitor, being developed in combination with Xospata (gilteritinib), an inhibitor of FLT3, for the treatment of NPM1-mutated acute myeloid leukemia.
Product Name : KO-539
Product Type : Small molecule
Upfront Cash : Undisclosed
June 13, 2023
Lead Product(s) : Ziftomenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : BofA Securities
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Iadademstat,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1 with powerful differentiating effect in hematologic cancer. It is being investigated in with gilteritinib for relapsed/refractory AML harboring a FMS-like tyrosine kinas...
Product Name : ORY-1001
Product Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2023
Lead Product(s) : Iadademstat,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Blood and Marrow Transplant Clinical Trials Network
Deal Size : Not Applicable
Deal Type : Not Applicable
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
Details : Xospata (gilteritinib) is a FLT3 inhibitor with demonstrated activity against FLT3-ITD, a common driver mutation that presents with a high disease burden and poor prognosis, and FLT3-tyrosine kinase domain mutations.
Product Name : Xospata
Product Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2023
Lead Product(s) : Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Blood and Marrow Transplant Clinical Trials Network
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lanraplenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
Details : Lanraplenib (Lanra) has demonstrated favorable pharmacokinetic (PK), pharmacodynamic (PD) and safety in more than 250 trial participants, including healthy volunteers and patients with autoimmune diseases.
Product Name : Lanra
Product Type : Small molecule
Upfront Cash : Not Applicable
November 08, 2022
Lead Product(s) : Lanraplenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lanraplenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lanra (lanraplenib) is the company’s next-generation spleen tyrosine kinase (SYK) inhibitor. In addition to lanraplenib, Kronos Bio is also evaluating its lead investigational SYK inhibitor, entospletinib, in the Phase 3 patients with NPM1-mutated AML.
Product Name : Lanra
Product Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2022
Lead Product(s) : Lanraplenib,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Iadademstat,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : European Commission
Deal Size : $2.0 million
Deal Type : Funding
Details : The net proceeds will be used to evaluate efficacy and optimal dose of ORY-1001 (iadademstat), a novel, highly potent, and selective inhibitor of LSD1, plus Xospata (gilteritinib), an inhibitor of FLT3, in patients with relapsed/refractory AML with FLT3 ...
Product Name : ORY-1001
Product Type : Small molecule
Upfront Cash : Undisclosed
June 07, 2022
Lead Product(s) : Iadademstat,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : European Commission
Deal Size : $2.0 million
Deal Type : Funding
Lead Product(s) : ERAS-007,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ERAS-007 is a highly potent and selective small molecule ERK1/2 inhibitor. It is being evaluated in phase 1/2 clinical trials in combination with gilteritinib for the treatment of acute myeloid leukemia.
Product Name : ERAS-007
Product Type : Small molecule
Upfront Cash : Not Applicable
April 12, 2022
Lead Product(s) : ERAS-007,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable